DBV Technologies S.A. (DBVT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
177-181 Avenue Pierre Brossolette
Montrouge, 92120
France
Phone
33 1 55 42 78 78
Sector
Healthcare
Industry
Biotechnology
Employees
106
First IPO Date
October 22, 2014
| Name | Title | Pay | Year Born |
| Daniel Tassé | Chief Executive Officer & Director | 1.44M | 1960 |
| Virginie Simone Jeanine Verrechia Boucinha | Chief Financial Officer | 600,144 | 1969 |
| Pharis Mohideen | Chief Medical Officer | 1.02M | 1965 |
| Alan Kerr | Senior Vice President & Head of Global Regulatory Affairs | 0 | N/A |
| Kevin Malobisky | Chief Operations Officer | 0 | N/A |
| James Briggs | Chief Human Resources Officer | 0 | 1972 |
| Jonathan Neely | VP & Head of Investor Relations | 0 | N/A |
| Kevin Trapp | Chief Commercial Officer | 0 | 1967 |
| Pascal Wotling | Chief External Manufacturing & Supply Chain Officer | 0 | N/A |
| Michele F. Robertson | Chief Legal Officer | 0 | N/A |
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.